Experienced in Immune Thrombocytopenic Purpura (ITP)

Dr. Jatin Rana

Hematology Oncology | Hematology | Oncology
Infusion Center (Non-Oncology)-McLaren Greater Lansing
3520 Forest Rd Fl 2, 
Lansing, MI 
Experienced in Immune Thrombocytopenic Purpura (ITP)
Infusion Center (Non-Oncology)-McLaren Greater Lansing
3520 Forest Rd Fl 2, 
Lansing, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jatin Rana is a Hematologist Oncology specialist and a Hematologist in Lansing, Michigan. Dr. Rana is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Hemophilic Arthropathy, Hemophilia A, Paget Disease of the Breast, and Gastric Lymphoma.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Edward W Sparrow Hospital
Mclaren Greater Lansing
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Infusion Center (Non-Oncology)-McLaren Greater Lansing
3520 Forest Rd Fl 2, Lansing, MI 48910
Other Locations
McLaren Greater Lansing
401 W Greenlawn Ave, Lansing,, MI 48910

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015
A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015
Enrollment Status: Completed
Publish Date: February 06, 2024
Intervention Type: Drug
Study Drugs: Nab-Paclitaxel, Oxaliplatin, 5-FU, Leucovorin
Study Phase: Phase 2
A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Enrollment Status: Unknown
Publish Date: July 05, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Fulvestrant
Study Phase: Phase 2
View 7 Less Clinical Trials

5 Total Publications

Improving the Appropriate Prescribing of Olanzapine for Chemotherapy-Induced Nausea and Vomiting: A Quality Improvement Initiative for the Outpatient Oncology Practice.
Improving the Appropriate Prescribing of Olanzapine for Chemotherapy-Induced Nausea and Vomiting: A Quality Improvement Initiative for the Outpatient Oncology Practice.
Journal: Journal of the advanced practitioner in oncology
Published: December 05, 2025
Similar Doctors
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Justin A. Shaya
Oncology | Hematology | Hematology Oncology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Justin A. Shaya
Oncology | Hematology | Hematology Oncology

Iha Health Services Corporation

7575 Grand River Rd, 
Brighton, MI 
 (36.9 miles away)
734-712-7255
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Shaya is an Oncologist and a Hematologist in Brighton, Michigan. Dr. Shaya is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Prostate Cancer, Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia. Dr. Shaya is currently accepting new patients.

Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Asra Ahmed
Hematology
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Asra Ahmed
Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (48.7 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Asra Ahmed is a Hematologist in Ann Arbor, Michigan. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Reticulohistiocytoma, Histiocytosis, Non-Langerhans-Cell Histiocytosis, Rosai-Dorfman Disease, and Bone Marrow Aspiration.

Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Mohammad Omaira
Hematology Oncology | Hematology | Oncology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Mohammad Omaira
Hematology Oncology | Hematology | Oncology

Bronson Methodist Hospital

805 John St, 
Kalamazoo, MI 
 (62.1 miles away)
269-286-7170
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammad Omaira is a Hematologist Oncology specialist and a Hematologist in Kalamazoo, Michigan. Dr. Omaira is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Small Lymphocytic Lymphoma (SLL), Large-Cell Immunoblastic Lymphoma, and Chronic B-Cell Leukemia (CBCL). Dr. Omaira is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rana's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 76 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile